Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ondansetron + betahistine is a combination of two small molecule drugs used primarily for the prevention of postoperative nausea and vomiting (PONV), particularly in high-risk patients undergoing laparoscopic gynecological surgery. Ondansetron is a selective serotonin 5-HT3 receptor antagonist that blocks the action of serotonin, a natural substance that may cause nausea and vomiting. Betahistine acts as a strong antagonist at histamine H3 receptors and as a weak agonist at H1 receptors, increasing vasodilation and microcirculation in the inner ear, which can help reduce dizziness. The combination has been shown to be more effective than ondansetron alone in reducing both PONV and dizziness after surgery[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ondansetron + betahistine.